In consultation: Guidance and quality standards

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Consultation end date

Consultation end date

Type 1 selected

Type

Guidance programme

Showing 1 to 12 of 12

TitleConsultationTypeConsultation end date
Modular update to NICE manuals: EQ-5D-5L value setNICE general consultationNICE general
Prostate cancer: diagnosis and management (update)ScopingNICE guideline
Histamine dihydrochloride with interleukin-2 for maintenance treatment of acute myeloid leukaemia [ID1627]Draft guidanceTechnology appraisal guidance
Oveporexton for treating type 1 narcolepsy [ID6622]Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentatorsTechnology appraisal guidance
Donidalorsen for preventing recurrent attacks of hereditary angioedema in people 12 years and over [ID6457]Draft guidanceTechnology appraisal guidance
Ruxolitinib for treating moderate atopic dermatitis ID6602Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentatorsTechnology appraisal guidance
NICE-wide Topic Prioritisation: the manual (PMG46) 2026 Update ConsultationMethods / process manual consultationNICE process and methods
Efgartigimod for treating chronic inflammatory demyelinating polyneuropathy [ID6409]Draft guidanceTechnology appraisal guidance
Pirtobrutinib for treating relapsed or refractory chronic lymphocytic leukaemia after a BTK inhibitor [ID6269]Draft guidanceTechnology appraisal guidance
Zanidatamab for treating HER2-positive advanced biliary tract cancer after 1 or more lines of systemic treatment [ID6388]Final draft guidanceTechnology appraisal guidance
Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatments (managed access review of TA1023) [ID6653]Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentatorsTechnology appraisal guidance
Cabozantinib for treating advanced neuroendocrine tumours that have progressed after systemic treatment [ID6474]Final draft guidanceTechnology appraisal guidance

Results per page

  1. 10
  2. 25
  3. 50
  4. All